TransPot: The Translational Research Network for Prostate Cancer begins

The Translational Research Network for Prostate Cancer (TransPot) program will adopt an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer. This four year project has received over €2.5m in EU funding. It begun in January 2017 and will be led by Professor Hing Leung, Professor of Urology and Surgical Oncology at the University of Glasgow.

TransPot is a pan-European research training network focussed on Translational Cancer Research, Cancer Cell Biology and Applied Systems Biology/Systems Medicine and is composed of academic and industrial institutions from the United Kingdom, Finland, Germany, Greece and The Netherlands.

TransPot, as a Horizon 2020 Marie Skłodowska-Curie Innovative Training Network (ITN) will integrate the leading research scientists and laboratories in Europe with an interest in these research fields to recruit 11 Early Stage Researchers (ESRs) and offer them the unique opportunity to perform top-level and high impact research.

The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems level disease understanding in order to improve the prognosis and treatment of lethal prostate cancer, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant prostate cancer including castrate-resistant prostate cancer (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.

The project will incorporate the latest multi-disciplinary research technologies to understand lethal prostate cancer. The TransPot consortium will offer an innovative research training programme to ESRs to ensure that they can effectively operate in today’s multi-disciplinary programs. This will include both research (e.g. target validation and drug discovery; biomarker discovery and validation) and transferable skill sets (e.g. cross species onco-omics analysis; novel preclinical (culture/in vivo) models).

Advances achieved will facilitate personalized targeted medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

For further information regarding the TrasnPot project, please contact Hing Leung (